Savara再次向美国食品和药物管理局提交生物许可申请(BLA),以期为自身免疫性肺泡蛋白沉积症(Autoimmune PAP)提供Molbreevi的潜在治疗方案。
Savara再次向美国食品和药物管理局提交生物许可申请(BLA),以期为自身免疫性肺泡蛋白沉积症(Autoimmune PAP)提供Molbreevi的潜在治疗方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.